Health

Companies engaged in biotechnology, pharmaceuticals, research services, home healthcare, hospital operations, long‑term care, and the manufacture and supply of medical equipment and supplies. The sector also includes pharmaceutical retailers and providers of health‑information services. UK‑listed companies in this sector include AstraZeneca plc, GlaxoSmithKline plc, Smith & Nephew plc, Hikma Pharmaceuticals plc, ConvaTec Group plc, Spire Healthcare plc and EMIS Group plc.

GSK ViiV Healthcare reports Positive Findings for ultra long-acting HIV treatment Cabotegravir

GSK plc's ViiV Healthcare announces positive findings from a phase I study on cabotegravir ultra long-acting for HIV treatment. Exciting progress in long-acting medication development...

March 5, 2024

AstraZeneca and Daiichi Sankyo’s Dato-DXd validated by EMA for lung and breast cancer treatment

AstraZeneca and Daiichi Sankyo's datopotamab deruxtecan (Dato-DXd) receives EMA validation for lung and breast cancer treatments, advancing the potential for improved patient outcomes...

March 4, 2024

Haleon delivers strong organic growth of 8%, with Q4 organic growth over 6%

Haleon plc (LON:HLN) presents its full year results for 2023. Join the investor presentation by CEO Brian McNamara and CFO Tobias Hestler on 29th February 2024...

February 29, 2024

GSK settles another Zantac litigation case

GSK plc has reached a confidential settlement with Boyd/Steenvoord in a California state court case, avoiding a trial set for April 2, 2024...

February 29, 2024

AstraZeneca’s Voydeya recommended for PNH treatment in EU

AstraZeneca's Voydeya for PNH patients is recommended for EU approval. Learn about this promising treatment and its potential benefits for patients...

February 26, 2024

GSK plc 10.1% potential upside indicated by Berenberg Bank

GSK plc with ticker (LON:GSK) now has a potential upside of 10.1% according to Berenberg Bank.Berenberg Bank set a target price of 1,820 GBX for the company, which when compared..

February 22, 2024

ViiV Healthcare announces Superiority of long-acting HIV Therapy over daily oral treatment

ViiV Healthcare announces promising results from LATITUDE phase III trial, showing long-acting HIV treatment Cabenuva's superiority over daily oral therapy...

February 21, 2024

AstraZeneca’s Tagrisso plus chemotherapy appoved for lung cancer in the US

AstraZeneca's Tagrisso approved in the US for EGFRm non-small cell lung cancer with chemotherapy. FLAURA2 trial results show significant benefit...

February 19, 2024

GSK completes acquisition of Aiolos Bio, expanding respiratory biologics portfolio

GSK plc has completed the acquisition of Aiolos Bio, expanding its respiratory biologics portfolio with AIO-001, a potential treatment for asthma patients with low T2 inflammation. The acquisition includes an..

February 15, 2024

GSK receives FDA fast track designation for Bepirovirsen for Chronic Hepatitis B

GSK plc has received Fast Track designation from the FDA for bepirovirsen, an investigational drug for chronic hepatitis B treatment. This designation highlights the need for effective medications to address..

February 12, 2024

AstraZeneca reports Strong Growth and Pipeline Momentum in FY and Q4 2023

AstraZeneca reports strong FY and Q4 2023 results, with revenue growth, new medicine approvals, and optimistic growth projections for 2024...

February 8, 2024

GSK plc -5.0% potential downside indicated by Barclays

GSK plc with ticker (LON:GSK) now has a potential downside of -5.0% according to Barclays.Barclays set a target price of 1,575 GBX for the company, which when compared to the..

February 7, 2024

GSK’s RSV vaccine for adults 50-59 at increased risk accepted by FDA for Priority Review

GSK plc's application to extend its RSV vaccine indication to adults aged 50-59 at risk has been accepted by the FDA for priority review. If approved, it would be the..

February 6, 2024

GSK reaches confidential settlement with David Browne in Zantac case

GSK has reached a confidential settlement with David Browne, resolving a California state court case. The company will continue to defend itself in other Zantac cases...

February 1, 2024

GSK plc 2.6% potential upside indicated by Barclays

GSK plc with ticker (LON:GSK) now has a potential upside of 2.6% according to Barclays.Barclays set a target price of 1,575 GBX for the company, which when compared to the..

January 31, 2024

GSK plc delivers Strong Sales and Earnings Growth in 2023

GSK plc announces strong financial results, with sales and profits driven by broad-based performance and COVID-19 vaccine sales...

January 31, 2024

Haleon to sell ChapStick brand to Suave Brands Company

Haleon plc has entered into a binding agreement to sell the ChapStick brand to Suave Brands Company, generating $430 million in cash proceeds...

January 25, 2024

GSK plc .9% potential upside indicated by Barclays

GSK plc with ticker (LON:GSK) now has a potential upside of .9% according to Barclays.Barclays set a target price of 1,575 GBX for the company, which when compared to the..

January 19, 2024

GSK plc .9% potential upside indicated by Barclays

GSK plc with ticker (LON:GSK) now has a potential upside of .9% according to Barclays.Barclays set a target price of 1,575 GBX for the company, which when compared to the..

January 12, 2024

GSK’s Nucala approved in China for use in severe asthma

GSK plc (LON/NYSE: GSK) has announced that the China National Medical Products Administration has approved Nucala (mepolizumab) as an add-on maintenance treatment for severe eosinophilic asthma in adults and adolescents..

January 10, 2024

News and Interview Alerts

Company Presentations

Q&As

Hardman & Co

ICG Enterprise Trust FY’26 results: look to future realisations

11 June 2026

NB Private Equity Partners 2025 results: Looking to future realisations

29 May 2026

Chesnara Plc: Showing good operational progress

17 April 2026

Arbuthnot Banking Group Plc: 2025 lower margins, 2026 profit stability

1 April 2026

Green News

Quadrise reports progress on Valkor pilot deployment in Utah

12 June 2026

Thor Energy reports elevated hydrogen results at HY-Range project

9 June 2026

Drax agrees £548m cash acquisition of Bluefield Solar Income Fund

1 June 2026

Drax completes commissioning of Hirwaun Power Station

29 May 2026

View all Sustainable sectors, Plcs and news >>

Search

Latest Interviews

BrokerTalk

Valeura Energy Delivers Strong Operational Momentum in Thailand – Canaccord Genuity

16 October 2025

Norcros plc completes earnings-enhancing Fibo acquisition, Equity Development

15 October 2025

EDX Medical Advances Commercial Strategy with TC100 Launch, Says Oberon Capital

10 October 2025

Pennant International broker maintains 95% share price upside on £3.8m contract wins

9 October 2025

Avation Clears the Runway for Growth Following Strong FY25 Results – Zeus Capital

6 October 2025

Funds

Agricultural commodities look mispriced as fertiliser risk builds | Ruffer Investment Company

15 June 2026

Diverse Income Trust: UK equity outlook and reconstruction proposal (LON:DIVI)

11 June 2026

Biotech Growth Trust reports strong one-year performance

11 June 2026

Ruffer Investment Company delivers positive year-to-date gains

11 June 2026

Finsbury Growth & Income Trust highlights portfolio value in May

9 June 2026

View all Funds, Market Insights and news >>

FTSE 100 News

UK Broker Ratings

Goodwin PLC (GDWN.L) Stock Analysis: A Strong Performer in Specialty Industrial Machinery

16 June 2026

Baltic Classifieds Group PLC (BCG.L) Investor Outlook: Unpacking a 36.97% Potential Upside

16 June 2026

Hilton Food Group (HFG.L) Stock Analysis: Exploring a 31.61% Potential Upside

16 June 2026

Bodycote PLC (BOY.L) Stock Analysis: Exploring a 19.15% Potential Upside for Investors

16 June 2026

Chemring Group PLC (CHG.L) Stock Analysis: A 24.57% Potential Upside Beckons Investors

16 June 2026

Health

GSK ViiV Healthcare reports Positive Findings for ultra long-acting HIV treatment Cabotegravir

GSK plc's ViiV Healthcare announces positive findings from a phase I study on cabotegravir ultra long-acting for HIV treatment. Exciting progress in long-acting medication development...

March 5, 2024

AstraZeneca and Daiichi Sankyo’s Dato-DXd validated by EMA for lung and breast cancer treatment

AstraZeneca and Daiichi Sankyo's datopotamab deruxtecan (Dato-DXd) receives EMA validation for lung and breast cancer treatments, advancing the potential for improved patient outcomes...

March 4, 2024

Haleon delivers strong organic growth of 8%, with Q4 organic growth over 6%

Haleon plc (LON:HLN) presents its full year results for 2023. Join the investor presentation by CEO Brian McNamara and CFO Tobias Hestler on 29th February 2024...

February 29, 2024

GSK settles another Zantac litigation case

GSK plc has reached a confidential settlement with Boyd/Steenvoord in a California state court case, avoiding a trial set for April 2, 2024...

February 29, 2024

AstraZeneca’s Voydeya recommended for PNH treatment in EU

AstraZeneca's Voydeya for PNH patients is recommended for EU approval. Learn about this promising treatment and its potential benefits for patients...

February 26, 2024

GSK plc 10.1% potential upside indicated by Berenberg Bank

February 22, 2024

ViiV Healthcare announces Superiority of long-acting HIV Therapy over daily oral treatment

ViiV Healthcare announces promising results from LATITUDE phase III trial, showing long-acting HIV treatment Cabenuva's superiority over daily oral therapy...

February 21, 2024

AstraZeneca’s Tagrisso plus chemotherapy appoved for lung cancer in the US

AstraZeneca's Tagrisso approved in the US for EGFRm non-small cell lung cancer with chemotherapy. FLAURA2 trial results show significant benefit...

February 19, 2024

GSK completes acquisition of Aiolos Bio, expanding respiratory biologics portfolio

February 15, 2024

GSK receives FDA fast track designation for Bepirovirsen for Chronic Hepatitis B

February 12, 2024

AstraZeneca reports Strong Growth and Pipeline Momentum in FY and Q4 2023

AstraZeneca reports strong FY and Q4 2023 results, with revenue growth, new medicine approvals, and optimistic growth projections for 2024...

February 8, 2024

GSK plc -5.0% potential downside indicated by Barclays

February 7, 2024

GSK’s RSV vaccine for adults 50-59 at increased risk accepted by FDA for Priority Review

GSK plc's application to extend its RSV vaccine indication to adults aged 50-59 at risk has been accepted by the FDA for priority review. If approved, it would be the first vaccine for this population. The application is supported by positive phase III trial results...

February 6, 2024

GSK reaches confidential settlement with David Browne in Zantac case

GSK has reached a confidential settlement with David Browne, resolving a California state court case. The company will continue to defend itself in other Zantac cases...